Surgical Innovations Group (AIM:SUN) provided a trading update ahead of its year end, December 31 2025, reporting softer-than-anticipated sales in the final quarter.
The company said performance was affected by a combination of external market factors across several regions.
It said a global flu epidemic reduced elective surgical procedures across Europe, APAC and other markets, and, this was compounded by continued industrial action within the NHS, which contributed to delays and capacity pressures, while a one-off quality issue with an OEM supplier constrained manufacturing during December.
As a result, Surgical Innovations now expects full-year revenue of approximately £11.5 million, with a corresponding impact on profitability. Net debt stood at £0.4 million as of 17 December 2025, and the board said it continues to closely monitor working capital.
“Whilst we are naturally disappointed with the external market forces having a direct impact on the group's performance, we remain confident in our reposable™ technology and the overall prospects of the group going forward," said chief executive David Marsh.
In London, the share was down 36.3% changing hands at 0.35p.